HBV Policy & Advocacy
San Francisco Hepatitis C Task Force Issues Recommendations
- Details
- Category: HBV Policy & Advocacy
- Published on Friday, 11 February 2011 12:41
- Written by San Francisco Hepatitis C Task Force
The San Francisco Hepatitis C Task Force issued a final report in late January, calling on the city to take steps to improve prevention, care, and treatment of hepatitis C virus (HCV) infection. Among the recommendations are expanded testing, establishment of a hepatitis C coordinator within the Department of Public Health, developing education and awareness campaigns, and opening a supervised safe infection facility.
AASLD and Trust for America's Health Call for Action on Hepatitis B and C
- Details
- Category: HBV Policy & Advocacy
- Published on Tuesday, 05 October 2010 13:42
- Written by Trust for America's Health
Millions of Americans are living with chronic hepatitis B or C, but many do not know they are infected and are not receiving appropriate care, according to a new report issued by the American Association for the Study of Liver Diseases (AASLD) and the Trust for America's Health (TFAH). Over years or decades, chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) infection can cause advanced liver disease -- including liver cirrhosis and hepatocellular carcinoma -- which is projected to be a growing public health concern in the coming years.
Advocates Rally in San Francisco and Washington to Raise Awareness and Demand Funding for Hepatitis B an C
- Details
- Category: HBV Policy & Advocacy
- Published on Friday, 21 May 2010 14:02
- Written by Liz Highleyman
Hepatitis advocates gathered in San Francisco and Washington, DC, on May 19 -- World Hepatitis Day -- to bring attention to chronic hepatitis B and C and to call for increased funding for public education, testing, treatment, and care. Speakers described their experiences with stigma, difficulty accessing treatment, and side effects and suboptimal effectiveness of current hepatitis C therapies, while expressing hope for new directing-acting HCV drugs that are expected to start becoming available in the next couple years.
Web Design and Development by